Search

everythinglearnresearchcommunity

for

Search:↓

Hair transplant tips and surgery as a last resort. Discussion includes medications, age considerations, and choosing the right surgeon.

User reports 12-week progress with HIMS spray, Minoxidil, micro-needling, and biotin. Notable baby hairs on crown and temples, hoping for further improvement.

User tried oral dut 0.5mg, oral min 5mg, topical RU 80mg, and weekly microneedling at 1.5mm for hair loss. Others commented on the significant improvement and potential for future hair transplant.

The user shared progress after two months using a topical formulation containing Dutasteride 0.25%, Minoxidil 5%, Cetirizine 1%, Melatonin 0.5%, Caffeine 2%, and Latanoprost 0.005%. The focus is on hair loss treatment results.

User shared 9-month hair regrowth progress using a Fin/Min spray from HIMS, with additional microneedling. Other users praised the results and discussed the effectiveness of topical treatments.

Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

A user shared their 10-month hair loss treatment progress using 1mg Fin, 2.5mg oral Min, Keto shampoo, dermastamping, and recently added Dut. Replies noted the user had great hair before and after treatment.

A female with PCOS and androgenetic alopecia is starting treatment with oral Minoxidil, topical Minoxidil 5% with finasteride, and plans to add mesotherapy. She previously tried anti-androgenic contraceptive pills but couldn't tolerate them and is using Myo Inositol for weight management.

The conversation discusses the removal of Breezula phase II 12-month results by Cassiopea and the search for the original data. Concerns were raised about potential negative long-term effects on hair growth, such as androgen receptor upregulation.

A 23-year-old male used 1.25mg finasteride every other day for 10 months without minoxidil, noticing results at the 4-month mark and experiencing a minor shed at the 8-month mark. He also added Nizoral to his routine and reported no side effects, maintaining consistent use at 7:00 PM.

Efforts to find a Canadian dermatologist in the US to prescribe H&W's topical finasteride for hair loss. The user is willing to fund a crowd-share effort to identify prospects.

The user experienced significant hair regrowth after 10 months of using Minoxidil and 8 months of Finasteride, despite an initial shedding phase. They reported minor initial side effects but overall positive results, with the crown area completely filled in.

Hair loss discussion mentions HMI-115 efficacy in 3 months after Phase II study. Users discuss treatment effectiveness and mention massive regrowth in previously bald areas.

A 24-year-old with a high Norwood scale is seeking advice on hair loss treatments and considering a second hair transplant. They currently use topical finasteride and minoxidil, castor oil, and a derma roller, and are advised to switch to oral dutasteride and minoxidil.

The conversation discusses biannual SCUBE3 injections and microneedling as treatments for hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

In this conversation, 4990 discussed various treatments for hair loss, including oral minoxidil, PRP, transplan, Jak inhibitors, Dutasteride, Finasteride, Olumiant, Ketoconazole, RU58841, microneedling, baricitinib, and CCCA. They recommended scalp biopsies in unclear cases of DUPA, twice weekly to twice daily shampooing for topical minoxidil users, and two sessions spaced one month apart with follow up at month three to determine the effectiveness of PRP treatment.

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.

First patient dosed with Pyrilutamide (Kintor) Phase III for hair loss treatment. Pyrilutamide differs from approved treatments as it competes with DHT to bind hair follicles, potentially reducing side effects.

A user shared their positive experience with the telehealth service DocBright, highlighting its affordability and effectiveness in prescribing finasteride, oral minoxidil, and ketoconazole. They noted the service's unique ability to provide a prescription at age 17 but criticized the unprofessional communication with the dermatologist.

The user's progress in treating their hair loss using finasteride, minoxidil, vitamins, and microneedling, with one person suggesting to wait six more months before considering a hair transplant. The other person agreed that a hair transplant would be nice.

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.

User shows temple area progress after hair transplant, using DUT every other day and oral Min 2.5 daily. Another user asks about number of grafts and cost.

The conversation is about someone inquiring if anyone has tried Olumiant or its active ingredient, Baricitinib, for hair loss, mentioning the cost and that they have ordered Baricitinib.

A user wants to add cetirizine tablets to their minoxidil bottle and asks how many 10mg tablets to crush for a 100ml bottle. They seek advice on the correct dosage.

The conversation discusses the lack of updates on GT20029 for hair loss treatment, with some users noting recent reports indicating ongoing data collection. There are mentions of other treatments like Pyrilutamide and Minoxidil.

The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.

9 Month Update: Topical Fin/Min (0.3%, 6%), Weekly Microneedle 1.5mm, 40 Years Old. User shares progress pictures and discusses hair loss treatments used.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.